These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23557064)

  • 1. Phosphodiesterase 4-targeted treatments for autoimmune diseases.
    Kumar N; Goldminz AM; Kim N; Gottlieb AB
    BMC Med; 2013 Apr; 11():96. PubMed ID: 23557064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
    Gooderham M; Papp K
    BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
    Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
    J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
    Kearns DG; Uppal S; Chat VS; Wu JJ
    J Drugs Dermatol; 2021 May; 20(5):582-583. PubMed ID: 33938697
    [No Abstract]   [Full Text] [Related]  

  • 8. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
    McCann FE; Palfreeman AC; Andrews M; Perocheau DP; Inglis JJ; Schafer P; Feldmann M; Williams RO; Brennan FM
    Arthritis Res Ther; 2010; 12(3):R107. PubMed ID: 20525198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
    Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.
    Palfreeman AC; McNamee KE; McCann FE
    Drug Des Devel Ther; 2013; 7():201-10. PubMed ID: 23569359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
    Sakkas LI; Mavropoulos A; Bogdanos DP
    Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Otezla, Warts and All, Racks Up Sales and Eyes Blockbuster Status.
    Reinke T
    Manag Care; 2017 Oct; 26(10):8-9. PubMed ID: 29068290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast (otezla) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 May; 56(1443):41-2. PubMed ID: 24869713
    [No Abstract]   [Full Text] [Related]  

  • 14. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R; Alikhan A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast for the treatment of psoriasis.
    Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
    Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Phosphodiesterase Inhibitors: A New Therapeutic Option in Inflammation and Autoimmunity.
    Hernández-Flórez D; Valor L
    Reumatol Clin; 2016; 12(6):303-306. PubMed ID: 27567299
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
    Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
    Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
    Moustafa F; Feldman SR
    Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
    Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
    Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.